· Published by Health Canada · Official notice
This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
Dear Health Care Professional,
Subject: Association of ACLASTAFootnote * (zoledronic acid 5 mg/100 mL) solution for intravenous infusion with renal dysfunction.
Novartis Pharmaceuticals Canada Inc. ("Novartis"), in collaboration with Health Canada, would like to provide you with important renal safety information on renal dysfunction based on post-marketing experience with ACLASTAFootnote *. Therefore, Novartis would like to reinforce the current recommendations for selecting appropriate patients for ACLASTAFootnote *.
The ACLASTANote de bas de page * Product Monograph, has been revised to further emphasize precautions that should be taken into account to minimize the risk of renal adverse reactions:
As of April 30, 2010 Novartis has received 265 spontaneous reports of renal impairment following administration of ACLASTAFootnote *, corresponding to a reporting rate of approximately 20 cases per 100,000 patient-years of exposure.
The following precautions should be taken to minimize the risk of renal adverse reactions:
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious overdose symptoms or other serious or unexpected adverse reactions in patients receiving ACLASTAFootnote* should be reported to Novartis Pharmaceuticals Canada Inc. or Health Canada at the following addresses:
Novartis Pharmaceuticals Canada Inc.
385 Bouchard blvd,
Dorval, Quebec, H9S 1A9
Telephone: 1-800-363-8883 (Medical Information)
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
To change your mailing address or fax number, contact the Market Authorization Holder (Industry).
Should you have any questions or require additional information regarding the use of ACLASTAFootnote * (zoledronic acid), please contact Novartis Pharmaceuticals Canada Inc., Medical Information Department at 1-800-363-8883.
Sincerely,
original signed by
Jean-Marie Leclerc, M.D. FRCP(C)
Chief Scientific Officer and Senior Vice-President Clinical and Regulatory Affairs
*ACLASTA is a registered trademark
ACLASTAFootnote* is approved for the treatment and prevention of osteoporosis in postmenopausal women, to increase bone mass in men with osteoporosis, for treatment and prevention of glucocorticoid-induced osteoporosis and for the treatment of Paget's disease of bone.